Restoring metabolic balance

Harnessing precision-targeted drug formulations for the treatment and prevention of metabolic disorders such as obesity and related diseases

Our Approach

Metabolic Diseases: A Global Epidemic

Metabolic disorders such as obesity or type 2 diabetes have presented as a health and economic problem of global proportions over the past 40 years. Perturbations of the endocrine balance are a hallmark of most of these disorders. Safely restoring metabolic balance is the key to treating and preventing them.

LEARN MORE

APH-012

We believe that our lead candidate, APH-012, has the potential to revolutionize the treatment of metabolic diseases like obesity and type 2 diabetes. APH-012 uniquely induces the release of the full spectrum of enteral hormones that control appetite, hunger, satiety, glucose metabolism, and other homeostatic functions.

LEARN MORE

Programs

PHASE 2 TRIALS IN OBESITY AND PREDIABETES

APH-012 is being evaluated in two Phase 2 trials. The first proof-of-concept study in individuals with obesity evaluates APH-012’s ability to change weight and other key parameters hallmarking multiple metabolic diseases associated with obesity in a placebo controlled design. The second trial is evaluating APH-012’s ability to help prevent type 2 diabetes.

LEARN MORE

News

Aphaia Pharma at the 10th LSX World Congress

04/16/2024

Aphaia Pharma to Participate in a Panel Discussion at the 10^th LSX World Congress

ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, April 16, 2024 –
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, M.D., Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 10^th LSX World Congress, taking place April 29-30, 2024 in London, England.

First Patient in Phase 2 Trial Evaluating APH-012 for Prediabetes

04/25/2023

Aphaia Pharma Announces Dosing of First Patient in its Phase 2 Trial Evaluating its Lead Candidate APH-012 for Prediabetes
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced the first patient has been dosed in a Phase 2 study evaluating the safety and efficacy of its lead candidate, APH-012, to improve glucose tolerance in patients with prediabetes.

Participation in the LSX Leaders Inv€$tival Showcase

11/07/2022

Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase
Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of metabolic diseases, today announced that it will participate in the LSX Leaders Inv€$tival Showcase, to be held November 14, 2022, in London as the pre-day to the Jefferies London Healthcare Conference, November 15-17, 2022.

All news